微创R1血管切除治疗肝细胞癌可行性与安全性
本研究基于前瞻性数据库纳入2018年4月至2023年5月接受根治性肝切除的58例患者,其中22例(38%)行微创R1血管手术,36例(62%)行非R1血管手术。结果显示两组在失血量、手术时间和R1par切除率等方面具有可比性,微创R1血管手术治疗肝细胞癌安全可行。
要点
- 微创R1血管手术治疗肝细胞癌安全可行。
- R1血管组肿瘤更靠近主肝静脉和Glissonean蒂。
- 两组失血量、手术时间和R1par切除率无显著差异。
核心结论
- 微创R1血管手术对肝细胞癌患者安全可行。
研究设计与样本
- 队列研究,从前瞻性机构数据库连续纳入2018年4月至2023年5月接受根治性肝切除术的患者58例。
主要发现
- 58例中22例(38%)行微创R1血管手术,36例(62%)行非R1血管手术。
- R1血管组浸润肝段数更多(2 vs. 1,p=0.04)。
- R1血管组肿瘤距主肝静脉更短(5 mm vs. 21 mm,p<0.001),距Glissonean蒂更短(4 mm vs. 26 mm,p<0.001)。
- 两组中位失血量(600 ml vs. 500 ml,p=0.41)、手术时间(264 min vs. 231 min,p=0.13)和R1par切除率(5% vs. 3%,p=0.72)具有可比性。
临床怎么用
- 对于肝细胞癌患者,在术前评估和术中超声引导下可考虑微创R1血管手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In recent studies addressing colorectal liver metastases and HCC, R1 vascular surgery has demonstrated safety and oncological adequacy. Recognizing that patient prognosis after liver surgery for HCC depends more on preserving an adequate future liver remnant than on the width of the surgical margin, this surgical approach has achieved rising interest. However, data for its feasibility and safety for minimally invasive approaches for HCC resections are limited. Therefore, the aim of our study was to determine the feasibility and safety of minimally invasive R1 vascular surgery for HCC. METHODS: Consecutive patients who underwent curative hepatectomies between April 2018 and May 2023 were identified from a prospectively collected institutional database. Intraoperative ultrasound was performed to guide the resection, confirm the preoperative finding regarding the tumor's relation to the main vessels, and exclude any undetected vascular invasion or additional lesions. Postoperative complications were graded according to the Clavien-Dindo classification. RESULTS: Among 58 patients included, 22 (38%) underwent minimally invasive R1vasc surgery for HCC and 36 (62%) non-R1vasc surgery. In the MI-R1vasc surgery group, there were significantly more infiltrated liver segments (2 vs. 1, p = 0.04) and a shorter tumor distance to the main hepatic veins (5 mm vs. 21 mm, p < 0.001) and Glissonean pedicles (4 mm vs. 26 mm, p < 0.001) than in MI-non-R1vasc surgery group. The comparisons of the type of surgical resection revealed similar findings between the study groups, with non-anatomic resections and segmentectomies being the most frequently performed resections. The median blood loss (600 ml vs. 500 ml, p = 0.41), operative time (264 min vs. 231 min, p = 0.13), and R1par resection rate (5% vs. 3%, p = 0.72) were comparable in both groups. Other intra- and postoperative outcomes were also comparable between the two groups. CONCLUSION: Minimally invasive R1 vascular surgery is safe and feasible for patients with Hepatocellular Carcinoma.
引用
- Abdelhadi S, Sandra-Petrescu F, Vassilev G, et al. Feasibility and safety of minimally invasive R1 vascular surgery for hepatocellular carcinoma: a cohort study. Surg Endosc. 2024. PMID: 39681679. doi:10.1007/s00464-024-11476-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。